Open Access
| Issue |
BIO Web Conf.
Volume 154, 2025
15th International Conference on Global Resource Conservation (ICGRC 2024) in conjunction with the 1st International Conference on Jamu and Alternative Medicine (ICJAM 2024)
|
|
|---|---|---|
| Article Number | 02003 | |
| Number of page(s) | 8 | |
| Section | Biotechnology and Bioprospecting | |
| DOI | https://doi.org/10.1051/bioconf/202515402003 | |
| Published online | 28 January 2025 | |
- Y. Liu, Y. Qin, B. Wu, H. Peng, M. Li, H. Luo, L. Liu. DNA methylation in polycystic ovary syndrome: Emerging evidence and challenges. Reprod Toxicol. 2022 Aug; 111: 11–19. Epub (2022) [CrossRef] [PubMed] [Google Scholar]
- D. Baldani, L. Skrgatic, R. Ougouag. Polycystic Ovary Syndrome: Important Underrecognised Cardiometabolic Risk Factor in Reproductive-Age Women. Int J Endocrinol (2015) [Google Scholar]
- W. Wolf, R. Wattick, O. Kinkade, M. Olfert. Geographical Prevalence of Polycystic Ovary Syndrome as Determined by Region and Race/Ethnicity. Int J of Environmental Research and Public Health, 15(11), 2589 (2018) [CrossRef] [Google Scholar]
- H. Zhao, J. Zhang, X. Cheng, et al. Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation, and treatment. J Ovarian Res, 16, 9 (2023) [CrossRef] [PubMed] [Google Scholar]
- H. Sadeghi, I. Adeli, D. Calina, A. Docea, T. Mousavi, M. Daniali, S. Nikfar, A. Tsatsakis, M. Abdollahi. Polycystic Ovary Syndrome: A Comprehensive Review of Pathogenesis, Management, and Drug Repurposing. Int. J. Mol. Sci., 23, 583 (2022) [CrossRef] [Google Scholar]
- D. Wishart, C. Knox, A. Guo, S. Shrivastava, M. Hassanali, P. Stothard, Z. Chang, J. Woolsey. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res, 34, D668–D672 (2006) [CrossRef] [PubMed] [Google Scholar]
- G. Attia, M. Almouteri, F. Alnakhli. Role of Metformin in Polycystic Ovary Syndrome (PCOS)-Related Infertility. Cureus, 15(8), e44493 (2023) [PubMed] [Google Scholar]
- C.-Y. Shi, J.-J. Xu, C. Li, J.-L. Yu, Y.-T. Wu, H.-F. Huang. A PPARG Splice Variant in Granulosa Cells Is Associated with Polycystic Ovary Syndrome. J. Clin. Med., 11, 7285. (2022) [CrossRef] [Google Scholar]
- K.-K. Ryan, B. Li, B.-E. Grayson, E.-K. Matter, S.-C. Woods, R.-J. Seeley. A role for central nervous system PPAR-γ in the regulation of energy balance. Nat Med, 17, 623626 (2011) [Google Scholar]
- M. Ahmadian, J. Suh, N. Hah, C. Liddle, A. Atkins, M. Downes, R. Evans. PPARγ signaling and metabolism: the good, the bad and the future. Nature Medicine, 99(5), 557–566 (2013) [CrossRef] [PubMed] [Google Scholar]
- B. Ramly, N. Afqah, Z.-A. Mohamed. Protein–protein interaction network analysis reveals several diseases highly associated with polycystic ovary syndrome. Int J Mol Sci., 20, 2959 (2019) [CrossRef] [PubMed] [Google Scholar]
- S. Willems, L. Gellrich, A. Chaikuad, S. Kluge, O. Werz, J. Heering. Endogenous vitamin E metabolites mediate allosteric PPARγ activation with unprecedented coregulatory interactions. Cell Chem Biol, 28(10), 1489–1500 (2021) [CrossRef] [PubMed] [Google Scholar]
- A. Najmi, M.-S. Alam, N. Thangavel, M. Taha, A.-M. Meraya, M. Albratty M. Synthesis, molecular docking, and in vivo antidiabetic evaluation of new benzylidene2,4-thiazolidinediones as partial PPAR-γ agonists. Sci Rep, 13(1), 19869 (2023) [CrossRef] [PubMed] [Google Scholar]
- T. Pantsar, A. Poso. Binding Affinity via Docking: Fact and Fiction. Mol Basel Switz, 23(8), 1899 (2018) [Google Scholar]
- J.-B Bruning, M. Chalmers, S. Prasad, S. Busby, T. Kamenecka, Y. He Y, et al. Partial Agonists Activate PPARγ Using a Helix 12 Independent Mechanism. Structure, 15(10), 1258–71 (2007) [CrossRef] [PubMed] [Google Scholar]
- L. Han, W.-J Shen, S. Bittner, F. Kraemer, S. Azhar. PPARs: Regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-beta/delta and PPARgamma. Future Cardiol, 13, 279–296 (2017) [CrossRef] [PubMed] [Google Scholar]
- A. Christofides, E. Konstantinidou, C. Jani, V. Boussiotis. The role of peroxisome proliferator-activated receptors (PPAR) in immune responses. Metabolism, 114, 154338 (2021) [CrossRef] [PubMed] [Google Scholar]
- W. Chen W, Y. Pang. Metabolic Syndrome and PCOS: Pathogenesis and the Role of Metabolites. Metabolites, 11, 869 (2021) [CrossRef] [PubMed] [Google Scholar]
- M. Shokrpour, F. Foroozanfard, Ebrahimi, Z. Vahedpoor Z, E. Aghadavod, A. Ghaderi, Z. Asemi. Comparison of myo-inositol and metformin on glycemic control, lipid profiles, and gene expression related to insulin and lipid metabolism in women with polycystic ovary syndrome: A randomized controlled clinical trial. Gynecol. Endocrinol, 35, 406–411 (2019) [CrossRef] [PubMed] [Google Scholar]
- A. Rutz, J. Bisson, P. Allard. The LOTUS Initiative for Open Natural Products Research: frozen dataset union wikidata (with metadata). Zenodo (2023) [Google Scholar]
- A.-D. Genazzani. Inositol as putative integrative treatment for PCOS. Reproductive BioMedicine Online, 33(6) (2016) [Google Scholar]
- B. Fauser, B. Tarlatzis, R.-W. Rebar, R.-S. Legro, A.-H. Balen, R. Lobo, E. Carmina, J. Chang, B.-O. Yildiz, J.S. Laven, J. Boivin. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertility and sterility, 97(1), 28–38 (2012). [CrossRef] [PubMed] [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.